Auna's Q4 Mexico Stabilization Shows Progress but Financial Recovery Remains Unproven

What happened

Auna's recent article highlights Q4 2025 stabilization in Mexico operations, with oncology revenues jumping 35% sequentially and new insurer deals like ISSSTELEON positioning the business for 2026 growth. However, the DeepValue master report cautions that despite two consecutive quarters of volume gains, Mexico's financial performance in 3Q25 still showed a 12% YoY revenue decline and a 29% EBITDA drop, indicating operational improvements have not yet translated into profitability recovery. The new deals could enhance patient access and drive volumes, but the report underscores elevated leverage at ~3.6x and the ~$500 million Mexico investment plan, which risks equity dilution if not funded prudently. Additionally, unresolved IT system disruptions at Doctors Hospital and lack of auditable KPIs for utilization pose ongoing risks to sustained growth, as noted in the report's downside boundaries. Thus, while Q4 momentum is positive, investors must await concrete evidence of YoY financial inflection and deleveraging before reassessing the stock.

Implication

The Q4 sequential improvements are a step forward but do not yet alter the core investment thesis, as YoY financial recovery remains unproven and leverage is still high. New insurer deals may boost volumes, but operational bottlenecks like IT issues must be resolved to convert these into sustainable profitability. Elevated leverage at ~3.6x and the looming $500 million capex plan create significant dilution risk if equity is issued at depressed prices, potentially eroding per-share value. Monitoring should focus on upcoming earnings reports for signs of Mexico's YoY revenue and EBITDA inflection, as well as any financing announcements that could impact capital structure. Until these checkpoints are met, the stock offers limited margin of safety and remains speculative, aligning with the DeepValue report's WAIT rating.

Thesis delta

The Q4 stabilization news reinforces the expectation of sequential volume gains but does not shift the thesis, as YoY financial turnaround is still pending and leverage concerns persist. Investors should continue to prioritize evidence of Mexico revenue and EBITDA improvement by 2Q26 and clarity on non-dilutive funding for the expansion plan before considering a more bullish stance.